Expert on female sexual dysfunction disorder and CNS drug safety to outline challenges in development of combination therapies for CNS disorders. NEW YORK, Oct. 31, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual…
NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…
JERSEY CITY, N.J., March 3, 2014 /PRNewswire/ — S1 Biopharma today announced its plan to initiate Phase 2a clinical trials in the third quarter of this year for Orexa (S1P-205), its first-in-class therapy to treat male Hypoactive Sexual Desire Disorder…
Activity of Lorexys Requires Precise Ratio of Active Components, Trazodone and Bupropion JERSEY CITY, N.J., July 29, 2013 — S1 Biopharma, Inc., a developer of first-in-class drugs for sexual dysfunction in women and men, today announced enrollment and dosing of premenopausal…
Developer of the Only Non-Hormonal Therapy for HSDD in Women Announces S1P-205, the Only Therapy for HSDD in Men Jersey City, NJ — May 14, 2012 —S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder…